JMP Securities Keeps Their Hold Rating on Intercept Pharma (ICPT)

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Hold rating on Intercept Pharma (ICPTResearch Report). The company’s shares opened today at $15.71.

According to TipRanks, Wolleben is a 4-star analyst with an average return of 13.1% and a 41.52% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and BioCryst.

Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $22.57, implying a 43.67% upside from current levels. In a report released on January 13, RBC Capital also maintained a Hold rating on the stock with a $15.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Intercept Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $77.59 million and a net profit of $267.45 million. In comparison, last year the company earned a revenue of $66.64 million and had a GAAP net loss of $3.63 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Read More on ICPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More